None listed
Conditions
Brief summary
The MINI-MAP Trial is testing whether different blood pressure targets affect outcomes in critically ill patients who need medications called vasopressors to maintain their blood pressure. Patients will be randomly assigned to one of three minimum blood pressure targets (60, 65, or 70 mmHg) to determine which approach leads to better recovery and fewer complications. The study hypothesis is that using lower blood pressure targets will reduce the need for vasopressor medications and improve patient outcomes. This research aims to help doctors determine the safest and most effective blood pressure goals for patients in intensive care units.
Interventions
Titration of vasopressors to achieve the prescribed mean arterial pressure (MAP) target from randomisation to day 90 of ICU admission, death, or ICU discharge
Three groups of prescribed one of three minimum MAP targets, 60, 65 or 70 mmHg. The aim will be to use the lowest amount of vasopressor possible to achieve the specified target. The titration of vasopressor to the prescribed minimum MAP will be performed by the treating team including the bedside nurse, and medical staff.
The choice of
Titration of vasopressors to achieve the prescribed mean arterial pressure (MAP) target from randomisation to day 90 of ICU admission, death, or ICU discharge Three groups of prescribed one of three minimum MAP targets, 60, 65 or 70 mmHg. The aim will be to use the lowest amount of vasopressor possible to achieve the specified target. The titration of vasopressor to the prescribed minimum MAP will be performed by the treating team including the bedside nurse, and medical staff. The choice of vasopressor is up to the treating clinician. Examples of vasopressors will be noradrenaline, vasopressin, metaraminol, phenylephrine, adrenaline, and angiotension II. All vasopressors will be administered by intravenous infusion. The monitoring of MAP and adjustment of vasopressors will occur continuously. Compliance will the study protocol will be monitored and reported back to sites by using the electronic medical records.
Sponsors
Metro South Health
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Adult (greater than or equal to 18 years of age) patient receiving a vasopressor in the ICU during an unplanned admission.
Exclusion criteria
1. Vasopressors being administered for greater than 12 hours. 2. A study MAP target is considered contraindicated, or a specific MAP target is considered indicated. 3. A brain injury or spinal cord injury. 4. Previously enrolled.
Outcome results
None listed